Greenwich LifeSciences is a clinical-stage biopharmaceutical company with zero revenue since its 2006 inception. Its sole asset is GLSI-100 (GP2 + GM-CSF), a cancer immunotherapy being evaluated in the Phase III Flamingo-01 trial targeting HER2/neu-positive breast cancer patients with residual disease. The company has no approved products and relies entirely on equity issuances to fund operations.
With $6.2M cash against a $9.9M annual operating burn and a stated $30M+ BLA completion cost, the company faces a structural funding deficit requiring continuous equity dilution, while carrying an $87.1M accumulated deficit and zero lifetime revenue across 19 years of operations.
If Flamingo-01 generates positive interim data, the asset could attract partnership or acquisition interest given the large breast cancer addressable market and the post-period stock price recovery to $25.36 per ATM share. The flexible trial design, including the ability to adjust enrollment rate and patient numbers, provides some cost management optionality that could extend the runway.
With $6.2M in cash at year-end 2025, a $9.9M annual operating burn rate, a $30M+ stated BLA completion cost, and no committed capital, the company faces a structural funding shortfall that requires continuous equity dilution at declining prices to survive. The company has generated zero revenue in 19 years of operation, carries an $87.1M accumulated deficit, and its entire enterprise value rests on a single Phase III trial with a binary outcome.
Management states that operating losses will continue to increase for the foreseeable future as clinical trial expenses rise. The company acknowledges that the total cost to complete an interim analysis and file a BLA could exceed $30 million and that additional capital will be required, with no committed source identified. No specific timeline or enrollment milestone guidance was provided.
Greenwich LifeSciences has no marketed products and competes in the HER2-positive breast cancer space against established therapies including trastuzumab, pertuzumab, and T-DM1, as well as multiple clinical-stage immunotherapy programs. The company's only differentiation claim is the GP2 peptide mechanism and its broad HER2 expression targeting across all expression levels, though this remains unvalidated by Phase III data. No partnership, licensing revenue, or co-development agreement provides external validation of the asset.